Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05857904

Clinical Outcomes of CT-FFR Versus QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain

This study is a multicenter, prospective, blinded (blinding of clinical evaluators), randomized controlled, event-driven non-inferiority clinical trial. Eligible subjects who meet the inclusion criteria will be registered in the central randomization system and randomized in a 1:1 ratio to either the experimental group (CT-FFR guided group) or the control group (QFR guided group).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zhongshan Hospital, Fudan University

Shanghai, Shagnhai, 200032, China

About this study

This study is a multicenter, prospective, blinded, randomized controlled trial with event-driven non-inferiority design (blinding of clinical evaluators). A total of 4,648 participants will be recruited and randomly assigned to the CT-FFR guided group or the QFR guided group in a 1:1 ratio. Patients in the experimental group (CT-FFR guided group) will undergo three-dimensional reconstruction of coronary arteries and CT-FFR calculation using coronary CT angiography (CCTA) images and the RuiXin-FFR software. The CT-FFR results will be interpreted and analyzed by the researchers. If the CT-FFR value is >0.8, patients will receive medical therapy only, while if the CT-FFR value is ≤0.8, patients will undergo further coronary angiography to determine the appropriate treatment strategy (PCI, CABG, or medical therapy), based on the anatomical features of the lesion and CT-FFR results. Patients in the control group (QFR guided group) will undergo invasive coronary angiography (ICA) and QFR calculation based on ICA images. If the QFR value is ≤0.8 and the lesion is suitable for intervention, patients will receive PCI, while if the QFR value is >0.8, medical therapy will be recommended. Both groups will be followed up for clinical outcomes, health economics indicators, and quality of life at 1 month, 6 months, 1 year, 2 years, and 3 years. The occurrence of major adverse cardiovascular events (MACE) will be compared between the two groups. The study will also assess the effectiveness, safety, and economic value of CT-FFR in guiding diagnosis and treatment decisions for patients with stable angina, using QFR guided PCI as a control, with a non-inferiority comparison.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • with stable chest pain who underwent CCTA and have at least 1 lesion with a percent diameter stenosis (DS%) between 50% and 90% in a coronary artery with a ≥2.5 mm reference vessel diameter by visual assessment.These patients plan to undergo further non-invasive or invasive diagnosis and treatment.
  • Able to undergo invasive coronary angiography (ICA)
  • Capable of complying with the study procedures and fully understand the informed consent form approved by the ethics committee, and provide voluntary consent.

Exclusion criteria

General exclusion criteria:

  • Patients with acute coronary syndrome requiring urgent revascularization.
  • Patients with unstable angina, including those with first-onset chest pain within 48 hours, CCS III or higher first-onset angina, those whose angina has worsened to CCS III or IV within a short period of time, or those with rest angina lasting more than 20 minutes.
  • Patients with iodine contrast agent allergy.
  • Pregnant or lactating women.
  • Patients with severe congestive heart failure (NYHA III-IV or LVEF <30%) or acute pulmonary edema.
  • Patients with severe renal insufficiency (creatinine >150μmol/L or estimated - -glomerular filtration rate calculated by the Cockcroft-Gault formula <45ml/kg/1.73 m2).
  • Patients with other comorbidities and an expected survival time of less than 1 year.
  • Patients who, for any other reason, are considered by the investigators to be unsuitable for inclusion in the study or unable to complete the study and follow-up.

Coronary CTA and coronary angiography exclusion criteria:

  • Patients with a body mass index >35 when undergoing coronary CT testing, resulting in poor CT image quality due to motion artifacts, severe calcification, or inadequate iodine contrast agent filling.
  • Patients with a history of coronary artery bypass grafting (CABG).
  • Target lesions related to acute myocardial infarction.
  • Target lesions involving left main stem disease.
  • Target lesions involving myocardial bridging.
  • Target lesions involving in-stent restenosis.
  • Low-quality angiography due to poor visualization of vascular boundaries or poor iodine contrast agent filling.
  • Excessive overlap of the stenotic segment or severe tortuosity of the target vessel, making QFR calculation impossible.

Regen

Treatment and study plan

CT-FFR

Device

CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.

QFR

Device

Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.

Primary outcomes

  1. 1-year MACE

    Time frame: 1-year

    Major Adverse Coronary Event (MACE) rates, defined as:

    • All cause death
    • myocardial infarction (MI)
    • Repeat myocardial revascularization
    • non-lethal stroke

Secondary outcomes

  1. MACE

    Time frame: 1-month, 6-month, 2-years, 3-years

    Major Adverse Coronary Event (MACE) rates, defined as:

    • All cause death
    • myocardial infarction (MI)
    • Repeat myocardial revascularization
    • non-lethal stroke
  2. All cause death

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    All cause death defined as:

    Cardiovascular death, non-cardiovascular death, death of unknown cause

  3. Non-fatal myocardial infarction (MI)

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    myocardial infarction (MI) defined as: Spontaneous myocardial infarction , perioperative myocardial infarction

  4. repeat myocardial

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    Repeat myocardial defined as:Planned revascularization,Unplanned revascularization

  5. non-lethal stroke

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    The American Heart Association/American Stroke Association (AHA/ASA) defines stroke as including the following types:CNS infarction,Ischemic stroke,Silent CNS infarction,Intracerebral hemorrhage,Subarachnoid hemorrhage,Cerebral venous thrombosis

  6. The definite and probable stent thrombosis (defined by ARC-2 criteria)

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    The definite and probable stent thrombosis (defined by ARC-2 criteria) including acute, subacute, late, and very late stent thrombosis within a specific time frame.

  7. Proportion of non-obstructive CAD detected by ICA examination

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    Proportion of non-obstructive CAD detected by ICA examination

  8. Health Economics Evaluation Endpoints

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    Cost-effectiveness analysis, cost-utility analysis.

    The information collected by the cost indicators is as follows:

    • Costs associated with initial hospitalization, including:
    • Estimated cost of major cardiovascular medication
    • Total medical expenses related to major cardiac adverse events occurring during outpatient and/or hospitalization
  9. Quality of life (QOL)

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    Quality of life (QOL) will be assessed using the EQ-5D-VAS questionnaire. Angina status will be assessed using the Seattle Angina Questionnaire.

  10. Cumulative radiation exposure

    Time frame: 1-month, 6-month, 1-year, 2-years, 3-years

    Cumulative radiation exposure within1-month, 6-month, 1-year, 2-years and 3-years of study entry included all cardiovascular tests and invasive procedures, including CTA, myocardial perfusion imaging, and ICA.

Study contacts

Contact information is provided by the study sponsor or research team.

chenguang Li, doctor

CONTACT

[email protected]

13816767665

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Registry information

Official study title

Clinical Outcomes of CoroNary CTA-Derived FFR Versus ICA-Derived QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain

Acronym: CONFIDENT

Important dates

Study start
2023
Primary completion
2025
Study completion
2028
First posted
May 15, 2023
Registry last updated
May 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.